InvestSMART

Paradigm Biopharmaceuticals Limited (ASX: PAR) - Announcements

- Current share price for PAR : $0.180

ASX company news and announcements for Paradigm Biopharmaceuticals Limited (PAR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Paradigm Biopharmaceuticals Limited (PAR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Paradigm Biopharmaceuticals Limited (PAR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Paradigm Biopharmaceuticals Limited (PAR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$108 Results of Annual General Meeting 30 Nov 2016 12:40AM $0.435 $0.180 fallen by 58.62%
$108 Paradigm's hay fever clinical trial cleared to commence 22 Nov 2016 9:18AM $0.450 $0.180 fallen by 60%
$108 PAR Share Purchase Plan 2016 - Extension 17 Nov 2016 12:22AM $0.480 $0.180 fallen by 62.50%
$108 Cleansing Notice - Section 708A 28 Oct 2016 4:37PM $0.520 $0.180 fallen by 65.38%
$108 Appendix 3B 28 Oct 2016 11:50AM $0.500 $0.180 fallen by 64%
$108 Notice of Extraordinary General Meeting/Proxy Form 28 Oct 2016 9:59AM $0.500 $0.180 fallen by 64%
$108 Appendix 4C - September 2016 quarter 28 Oct 2016 12:15AM $0.500 $0.180 fallen by 64%
$108 PAR Share Purchase Plan 2016 21 Oct 2016 9:18AM $0.535 $0.180 fallen by 66.36%
$108 Paradigms Placement heavily oversubscribed 18 Oct 2016 9:14AM $0.510 $0.180 fallen by 64.71%
$108 Trading Halt 14 Oct 2016 9:34AM $0.510 $0.180 fallen by 64.71%
$108 Paradigm Biopharmaceuticals updated corporate presentati 12 Oct 2016 12:45AM $0.585 $0.180 fallen by 69.23%
$108 Preclinical study underpins efficacy of Paradigm's RhinosulR 16 Sep 2016 9:07AM $0.555 $0.180 fallen by 67.57%
$108 Change of Director's Interest Notice 13 Sep 2016 11:37AM $0.550 $0.180 fallen by 67.27%
$108 Paradigm PPS a potential in the treatment of viral arthritis 7 Sep 2016 8:51AM $0.485 $0.180 fallen by 62.89%
$108 Appendix 4G 31 Aug 2016 5:05PM $0.430 $0.180 fallen by 58.14%
$108 Full Year Statutory Accounts 31 Aug 2016 5:02PM $0.430 $0.180 fallen by 58.14%
$108 Preliminary Final Report 31 Aug 2016 4:57PM $0.430 $0.180 fallen by 58.14%
$108 Paradigm PPS nasal spray to treat Allergic Rhinitis 19 Aug 2016 9:42AM $0.390 $0.180 fallen by 53.85%
$108 Appendix 3B 12 Aug 2016 2:29PM $0.355 $0.180 fallen by 49.30%
$108 Appendix 4C - quarterly 28 Jul 2016 5:37PM $0.370 $0.180 fallen by 51.35%
$108 Shares released from escrow 21 Jul 2016 4:24PM $0.360 $0.180 fallen by 50%
$108 Investor Roadshow Presentation 20 Jun 2016 9:26AM $0.330 $0.180 fallen by 45.45%
$108 Baker Young Stockbrokers Initiates Coverage on Paradigm 9 Jun 2016 9:57AM $0.320 $0.180 fallen by 43.75%
$108 Shareholders Update 9 Jun 2016 9:55AM $0.320 $0.180 fallen by 43.75%
$108 Investor Update Hayfever Allergic Rhinitis 25 May 2016 10:21AM $0.320 $0.180 fallen by 43.75%

651 - 675 of 721 results

Page 27 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.